Chief Technical Officer (CTO)
Dr. Shahnawaz Imam is an expert in endocrine autoimmune disease, having focused for the last 10 years together with Dr. Jaume on Type 1 Diabetes (T1D), thyroid autoimmunity and thyroid cancer, exploring the role of the microenvironment in onset and progression of autoimmune diseases like T1D and thyroid cancer. Dr. Imam is working specifically to address antigen-specific and non-specific immunotherapies and immune modulation therapies for treating autoimmune diseases. Dr. Imam’s long-term goal is to develop, implement, and disseminate interventions to reduce the burden of autoimmune diseases like T1D.
After completing a doctorate in veterinary medicine at the Indian Veterinary Research Institute (IVRI), one of the finest institutes of veterinary research in South-West Asia in 2003, Dr. Shanawaz Imam pursued a Research Fellowship for a doctorate at the prestigious Indian Council of Agricultural Research (ICAR). Dr. Imam subsequently moved to the United States for postdoctoral training in the Laboratory of Dr. Ginther first, and then joined Dr. Jaume’s group in the Department of Medicine, Division of Endocrinology, at the University of Wisconsin-Madison, School of Medicine and Life Sciences. In 2015, the group moved to the Division of Endocrinology-Diabetes and Metabolism, Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Ohio.
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.